Financial health
- The company holds more cash ($45M) than total debt ($1M).
- Operating income covered interest expense -299.2× in the latest year.
IRD Financials Opus Genetics, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $14M | -$50M | 0.0% | -271.9% | — | $1M | $45M |
| 2024 | $11M | -$58M | 0.0% | -564.7% | — | $0 | $30M |
| 2023 | $19M | -$10M | 0.0% | -55.5% | — | — | $51M |
| 2022 | $40M | $18M | 0.0% | 45.7% | — | — | $43M |
| 2021 | $589000 | -$57M | 0.0% | -3854.8% | — | — | $25M |
| 2020 | $0 | -$25M | — | — | -$7M | — | — |
| 2019 | — | -$6M | — | — | -$4M | — | — |
| 2018 | — | -$14M | — | — | — | — | $9M |
| 2017 | — | -$25M | — | — | — | — | $9M |
| 2016 | — | -$9M | — | — | — | — | $12M |
| 2015 | — | -$14M | — | — | — | — | $10M |
| 2014 | — | -$19M | — | — | — | — | $10M |
| 2014 | — | -$87M | — | — | — | — | $40M |
| 2013 | — | -$9M | — | — | — | — | $19M |
| 2013 | — | -$70M | — | — | — | — | $15M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $2M | -$66M | 0.0% | -665.9% | — | $1M | $60M |
| Dec '25 | $4M | -$17M | 0.0% | -296.3% | — | $1M | $45M |
| Sep '25 | $3M | -$17M | 0.0% | -269.9% | — | $1M | $31M |
| Jun '25 | $3M | -$7M | 0.0% | -309.0% | — | $1M | $32M |
| Mar '25 | $4M | -$8M | 0.0% | -227.2% | — | — | $42M |
| Dec '24 | $4M | -$35M | 0.0% | -884.0% | — | $0 | $30M |
| Sep '24 | $4M | -$8M | 0.0% | -207.1% | — | — | $37M |
| Jun '24 | $1M | -$8M | 0.0% | -748.9% | — | — | $41M |
| Mar '24 | $2M | -$7M | 0.0% | -450.5% | — | — | $47M |
| Dec '23 | $2M | -$5M | 0.0% | -321.1% | — | — | $51M |
| Sep '23 | $12M | $6M | 0.0% | 53.5% | — | — | $42M |
| Jun '23 | $4M | -$5M | 0.0% | -146.7% | — | — | $40M |
| Mar '23 | $2M | -$6M | 0.0% | -350.5% | — | — | $39M |
| Dec '22 | $40M | $34M | 0.0% | 85.8% | — | — | $43M |
| Sep '22 | $0 | -$5M | — | — | — | — | $14M |
| Jun '22 | $0 | -$5M | — | — | — | — | — |
| Mar '22 | $0 | -$7M | — | — | — | — | — |
| Dec '21 | $0 | -$6M | — | — | — | — | $25M |
| Sep '21 | $489000 | -$4M | 0.0% | -865.4% | — | — | — |
| Jun '21 | $100000 | -$7M | 0.0% | -7137.0% | — | — | — |
Valuation over time
How the market has priced IRD against its own fundamentals since 2024-10 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 5.1× (Oct '24) to 21.4× (Jun '26).
P/S
Frequently asked questions
Is IRD growing its revenue and profit?
See the revenue and net-income charts above for Opus Genetics, Inc.'s multi-year trend.
How much debt does IRD have?
As of FY2025, Opus Genetics, Inc. reported $1M of total debt against $45M of cash; operating income covered interest expense -299.2×.
What is IRD's profit margin?
In FY2025, gross margin was —, operating margin -271.9%, and net margin -349.3%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.